BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36271301)

  • 1. Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
    Iwasawa T; Kosaka T; Yasumizu Y; Hongo H; Yanai Y; Baba Y; Matsumoto K; Nakamura K; Nishihara H; Oya M
    Int J Clin Oncol; 2022 Dec; 27(12):1867-1873. PubMed ID: 36271301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
    Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
    Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
    Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
    Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of
    Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
    Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
    Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
    J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing CDK12-Mutated Prostate Cancers.
    Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS
    Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
    Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
    Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
    Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of CDK12 alterations in a pan-cancer database.
    Pan E; Cabal A; Javier-DesLoges J; Patel D; Panian J; Lee S; Shaya J; Nonato T; Xu X; Stewart T; Rose B; Shabaik A; Cohen E; Kurzrock R; Tamayo P; McKay RR
    Cancer Med; 2022 Feb; 11(3):753-763. PubMed ID: 34898046
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Antonarakis ES; Isaacsson Velho P; Fu W; Wang H; Agarwal N; Sacristan Santos V; Maughan BL; Pili R; Adra N; Sternberg CN; Vlachostergios PJ; Tagawa ST; Bryce AH; McNatty AL; Reichert ZR; Dreicer R; Sartor O; Lotan TL; Hussain M
    JCO Precis Oncol; 2020; 4():370-381. PubMed ID: 32462107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.
    Zhang W; Zhou L; Di J
    Expert Rev Anticancer Ther; 2023 Feb; 23(2):207-216. PubMed ID: 36734254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
    Greenleaf AL
    Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
    Yanai Y; Kosaka T; Nakamura K; Aimono E; Matsumoto K; Morita S; Mikami S; Nishihara H; Oya M
    Cancer Sci; 2020 Dec; 111(12):4652-4655. PubMed ID: 33038052
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Schweizer MT; Ha G; Gulati R; Brown LC; McKay RR; Dorff T; Hoge ACH; Reichel J; Vats P; Kilari D; Patel V; Oh WK; Chinnaiyan A; Pritchard CC; Armstrong AJ; Montgomery RB; Alva A
    JCO Precis Oncol; 2020; 4():382-392. PubMed ID: 32671317
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
    bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lotan TL; Antonarakis ES
    Clin Cancer Res; 2021 Jan; 27(2):380-382. PubMed ID: 33199495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
    Qian K; Wang G; Ju L; Liu J; Luo Y; Wang Y; Peng T; Chen F; Zhang Y; Xiao Y; Wang X
    Oncogene; 2020 Oct; 39(44):6871-6878. PubMed ID: 32978518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
    Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
    Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK12 inactivation across solid tumors: an actionable genetic subtype.
    Marshall CH; Imada EL; Tang Z; Marchionni L; Antonarakis ES
    Oncoscience; 2019 May; 6(5-6):312-316. PubMed ID: 31360735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.